Regulated expression of alternate transcripts from the mouse oncostatin M gene: Implications for interleukin-6 family cytokines

Cytokine

Volumn 12, Issue 2, 2000, Pages 134-141

  Voyle, Roger B ^a   Rathjen, Peter D ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Alternate transcription; Cytokine antagonists; IL 6 family cytokines; Leukaemia inhibitory factor; Oncostatin M

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 6; ONCOSTATIN M;

ALTERNATIVE RNA SPLICING; ARTICLE; BONE MARROW; EXON; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; MOUSE; NONHUMAN; OPEN READING FRAME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RIBONUCLEASE PROTECTION ASSAY; TRANSLATION INITIATION;

EID: 0033923251     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1999.0541     Document Type: Article

References (65)

1. Bruce AG, Linsley PS, Rose TM. Oncostatin M. Prog Growth Factor Res. 4:1992;157-170.
2. Heinrich PC, Behrman I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/JAK/STAT pathway. Biochem J. 334:1998;297-314.
3. Malik N, Kallestad JC, Gunderson NL, Austin SD, Neubauer MG, Ochs V, Marquardt H, Zarling JM, Shoyab M, Wei CM, Linsley PS, Rose TM. Molecular cloning, sequence analysis, and functional expression of a novel growth regulator, oncostatin M. Mol Cell Biol. 9:1989;2847-2853.
4. Yoshimura A, Ichihara M, Kinjyo I, Moriyama M, Copeland NG, Gilbert DJ, Jenkins NA, Hara T, Miyajima A. Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway. EMBO J. 15:1996;1055-1063.
5. Xu M, Tsuji K, Ueda T, Mukouyama Y, Hara T, Yang F, Ebihara Y, Matsuoka S, Manabe A, Kikuchi A, Ito M, Miyajima A, Nakahata T. Stimulation of mouse and human primitive hematopoiesis by murine embryonic aorta-gonad-mesonephros-derived stromal cell lines. Blood. 92:1998;2032-2040.
6. Mukouyama Y, Hara T, Xu M, Tamura K, Donovan PJ, Kim H, Kogo H, Tsuji K, Nakahata T, Miyajima A. In vitro expansion of murine hematopoietic progenitors from the embryonic aorta-gonad-mesonephros region. Immunity. 8:1998;105-114.
7. Clegg CH, Rulffes JT, Wallace PM, Haugen HS. Regulation of an extrathymic T-cell development pathway by oncostatin M. Nature. 384:1996;261-263.
8. Hara T, Tamura K, Miguel MPD, Mukouyama Y, Kim H, Kogo H, Donovan PJ, Miyajima A. Distinct roles of oncostatin M and leukaemia inhibitory factor in the development of primordial germ cells and Sertoli cells in mice. Dev Biol. 201:1998;144-153.
9. Grenier A, Dehoux M, Boutten A, Arce-Vicioso M, Durrand G, Gougerot-Pociadelo M-A, Chollet-Martin S. Oncostatin M production and regulation by human polymorphonuclear neutrophils. Blood. 93:1999;1413-1421.
10. Horn D, Fitzpatrick WC, Gomper PT, Ochs V, Bolten-Hansen M, Zarling J, Malik N, Todaro GJ, Linsley PS. Regulation of cell growth by recombinant oncostatin M. Growth Factors. 2:1990;157-165.
11. Hara T, Ichihara M, Yoshimura A, Miyajima A. Cloning and biological activity of murine oncostatin M. Leukemia. 3:1997;449-450.
12. Rose TM, Welford DM, Gunderson NL, Bruce AG. Oncostatin M (OSM) inhibits the differentiation of pluripotent embryonic stem cells in vitro. Cytokine. 6:1994;48-54.
13. Robinson RC, Grey LM, Staunton D, Vankelecom H, Vernallis AB, Moreau JF, Stuart DI, Heath JK, Jones EY. The crystal structure and biological function of leukaemia inhibitory factor: Implications for receptor binding. Cell. 77:1994;1101-1116.
14. Kitchen D, Hoffman RC, Moy FJ, Powers R. Homology model for oncostatin M based on NMR structural data. Biochemistry. 37:1998;10581-10588.
15. Piquet-Pellorce C, Grey L, Mereau A, Heath JK. Are LIF and related cytokines functionally equivalent? Exp Cell Res. 213:1994;340-347.
16. Giovannini M, Selleri L, Hermanson GG, Evans GA. Localisation of the human oncostatin M gene (OSM) to chromosome 22q12, distal to the Ewing's sarcoma breakpoint. Cytogenet Cell Genet. 62:1993;32-34.
17. Jefferey E, Price V, Gearing DP. Close proximity of the genes for leukaemia inhibitory factor and oncostatin M. Cytokine. 5:1993;107-111.
18. Malik N, Haugen HS, Modrell B, Shoyab M, Clegg CH. Developmental abnormalities in mice transgenic for bovine oncostatin M. Mol Cell Biol. 15:1995;2349-2358.
19. Stahl J, Gearing DP, Wilson TA, Brown MA, King JA, Gough NM. Structural organisation of the genes for murine and human leukemia inhibitory factor. J Biol Chem. 265:1990;8833-8841.
20. Kato, Y, Kudo, T, Sato, S, Sutou, S, 1995, Bovine LIF gene sequence.
21. Stewart CL, Kaspar P, Brunet LJ, Bhatt H, Gadi I, Kontgen F. Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. Nature. 359:1992;76-79.
22. Mosley B. Dual oncostatin M (OSM) receptors. J Biol Chem. 271:1996;32635-32643.
23. Lindberg RA, Juan TS, Welcher AA, Sun Y, Cupples R, Guthrie B, Fletcher FA. Cloning and characterisation of a specific receptor for mouse oncostatin M. Mol Cell Biol. 18:1998;3357-3367.
24. Linsley PS, Kallestad J, Ochs V, Neubauer M. Cleavage of a hydrophillic C-terminal domain increases growth inhibitory activity of oncostatin M. Mol Cell Biol. 10:1990;1882-1890.
25. Lin L-FH, Mismer D, Lile JD, Armes LG III ETB, Vannice JL, Collins F. Purification, cloning, and expression of ciliary neurotrophic factor (CNTF). Science. 246:1989;1023-1025.
26. Pennica D, King KL, Shaw KJ, Luis E, Rullamas J, Luoh S-M, Darbonne WC, Knutzon DS, Yen R, Chien KR, Baker JB, Wood WI. Expression cloning of cardiotrophin 1, a cytokine that induces cardiac monocyte hypertrophy. Proc Natl Acad Sci U S A. 92:1995;1142-1146.
27. Kestler DP, Agarwal S, Cobb J, Goldstein KM, Hall RE. Detection and analysis of an alternatively spliced isoform of interleukin-6 mRNA in peripheral blood mononuclear cells. Blood. 86:1995;4559-4567.
28. Barut B, Chauhan D, Ushiyama H, Anderson KC. Interleukin-6 functions as an intracellular growth factor in hairy cell leukaemia in vitro. J Clin Invest. 92:1993;2346-2352.
29. Lu C, Kerbel RS. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol. 120:1993;1281-1288.
30. Roth M, Nauck M, Tamm M, Perruchoud AP, Ziesche R, Block LH. Intracellular interleukin 6 mediates platelet-derived growth factor-induced proliferation of nontransformed cells. Proc Natl Acad Sci U S A. 92:1995;1312-1316.
31. Kong B, Isozaki T, Sasaki S. IL-6 antisense-mediated growth inhibition of a choriocarcinoma cell line: an intracellular autocrine growth mechanism. Gynecol Oncol. 63:1996;78-84.
32. Haines BP, Voyle RB, Pelton TA, Forrest R, Rathjen PD. Complex conserved organisation of the mammalian LIF gene: A novel mechanism for regulated expression of intracellular and extracellular cytokines. J Immunol. 162:1999;4637-4646.
33. Voyle RB, Haines BP, Pera MF, Forest R, Rathjen PD. Human germ cell tumor lines express novel leukaemia inhibitory factor transcripts encoding differentially localised proteins. Exp Cell Res. 249:1999;199-211.
34. Baumann H, Ziegler SF, Mosley B, Morella KK, Pajovic S, Gearing DP. Reconstitution of the response to leukaemia inhibitory factor, oncostatin M, and cilliary neurotrophic factor in hepatoma cells. J Biol Chem. 268:1993;8414-8417.
35. Rathjen PD, Nichols J, Toth S, Edwards DR, Heath JK, Smith AG. Developmentally programmed induction of differentiation inhibiting activity and the control of stem cell populations. Genes Dev. 4:1990;2308-2318.
36. Robertson M, Chambers I, Rathjen P, Nichols J. Expression of alternative forms of differentiation inhibiting activity (DIA/LIF) during murine embryogenesis and in neonatal and adult tissues. Dev Genet. 14:1993;165-173.
37. Li M, Sendtner M, Smith A. Essential function of LIF receptor in motor neurons. Nature. 378:1995;724-727.
38. Yoshida K, Taga T, Saito M, Suematsu S, Kurmanogoh A, Tanaka T, Fujiwara H, Hirata M, Yamagami T, Nakahata T, Hirabayashi T, Yoneda Y, Tanaka K, Wang WZ, Mori C, Shiota K, Yoshida N, Kishimoto T. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and haematological disorders. Proc Natl Acad Sci U S A. 93:1996;407-411.
39. Dani C, Chambers I, Johnstone S, Robertson M, Ebrahimi B, Saito M, Taga T, Li M, Burdon T, Nichols J, Smith A. Paracrine induction of stem cell renewal by LIF-deficient ES cells: a new ES cell regulatory pathway. Dev Biol. 203:1998;149-162.
40. Koshimizu U, Taga T, Watanabe M, Saito M, Shirayoshi Y, Kishimoto T, Nakatsuji N. Functional requirement of gp130-mediated signaling for growth and survival of mouse primordial germ cells in vitro and derivation of embryonic germ (EG) cells. Development. 122:1996;1235-1242.
41. Smith AG, Nichols J, Robertson M, Rathjen PD. Differentiation inhibiting activity (DIA/LIF) and mouse development. Dev Biol. 151:1992;339-351.
42. Pergolizzi RG, Erster SH. Analysis of chromosome 22 loci in meningioma: Alterations in the leukemia inhibitory factor (LIF) locus. Mol Chem Neuropathol. 21:1994;189-216.
43. Takahashi R, Yokoji H, Misawa H, Hayashi M, Hu J, Deguchi T. A null mutation in the CNTF gene is not causally related to neurological diseases. Nature Genet. 7:1994;79-84.
44. Hann SR. Regulation and function of non-AUG-initiated proto-oncogenes. Biochimie. 76:1994;880-886.
45. Arnaud E, Touriol C, Boutonet C, Gensac M-C, Vagner S, Prats H, Prats A-C. A new 34 kDa isoform of human fibroblast growth factor 2 is cap dependently synthesised by using a non-AUG start codon and behaves as a survival factor. Mol Cell Biol. 19:1999;505-514.
46. Malyak M, Gutheridge JM, Hance KR, Dower SK, Freed JH, Arend WP. Characterisation of a low molecular weight isoform of IL-1 receptor antagonist. J Immunol. 161:1998;1997-2003.
47. Tagaya Y, Kurys G, Thies TA, Losi JM, Azimi N, Hanover JA, Bamford RN, Waldmann TA. Generation of nonsecretable interleukin 15 isoforms through alternate usage of signal peptides. Proc Natl Acad Sci U S A. 94:1997;14444-14449.
48. Grotzinger J, Kurapat G, Wollmer A, Kalai M, Rose-John S. The family of IL-6-type cytokines: specificity and promiscuity of the receptor complexes. Proteins. 27:1997;96-109.
49. Hudson KR, Vernallis AB, Heath JK. Characterisation of the receptor binding sites of human leukaemia inhibitory factor and creation of antagonists. J Biol Chem. 271:1996;11971-11978.
50. Staunton D, Hudson KR, Heath JK. The interactions of the cytokine-binding homology region and immunoglobulin-like domains of gp130 with oncostatin M: implications for receptor complex formation. Protein Eng. 11:1998;1093-1102.
51. Radka SF, Kallestad JC, Linsley PS, Shoyab M. The binding pattern of a neutralizing monoclonal antibody to mutant oncostatin M molecules is correlated with functional activity. Cytokine. 6:1994;55-60.
52. Kallestad JC, Shoyab M, Linsley PS. Disulfide bond assignment and identification of regions required for functional activity of oncostatin M. J Biol Chem. 266:1991;8940-8945.
53. Gabay C, Porter B, Fantuzzi G, Arend WP. Mouse IL-1 receptor antagonist isoforms: complementary DNA cloning and protein expression of intracellular isoform and tissue distribution of secreted and intracellular IL-1 receptor antagonist in vivo. J Immunol. 159:1997;5905-5913.
54. Muzio M, Polentarutti N, Poli G, DeGiola L, Introna M, Mantovani A, Colotta F. Cloning and characterisation of a new form of the interleukin 1 receptor antagonist. J Exp Med. 182:1995;623-628.
55. Watson JM, Lofquist AK, Rinehart CA, Olsen JC, Makarov SS, Kaufman DG, Haskill JS. The intracellular IL-1 receptor antagonist alters IL-1-inducible gene expression without blocking exogenous signalling by IL-1 beta. J Immunol. 155:1995;4467-4475.
56. Malyak M Jr. MFS, Abel AA, Hance KR, Arend WP. The differential production of three forms of IL-1 receptor atagonist by human neutrophils and monocytes. J Immunol. 161:1998;2004-2010.
57. Doetschman TC, Eistetter H, Katz M, Schmidt W, Kemler R. The in vivo development of blastocyst derived embryonic stem cell lines: formation of visceral yolk sac, blood islands and myocadium. J Embryol Exp Morph. 87:1985;27-45.
58. Smith AG. Culture and differentiation of embryonic stem cells. J Tissue Culture Methods. 13:1991;89-94.
59. Robertson EJ. Embryo-derived stem cell lines. Robertson EJ. Teratocarcinomas and Embryonic Stem Cells, A Practical Approach. 1987;71-112 IRL Press, Oxford.
60. Rathjen J, Lake J, Bettess MD, Washington JM, Chapman G, Rathjen PD. Formation of a primitive ectoderm like cell population, EPL cells, from ES cells in response to biologically derived factors. J Cell Sci. 112:1999;601-612.
61. Lake J, Rathjen J, Remiszewski J, Rathjen PD. Reversible programming of pluripotent cell differentiation. J Cell Sci. 2000.
62. Martin GR, Evans MJ. Differentiation of clonal lines of teratocarcinoma cells formation of embryoid bodies in vitro. Proc Natl Acad Sci U S A. 72:1975;1441-1445.
63. Edwards DR, Parfett CLJ, Denhardt D. Transcriptional regulation of two serum-induced RNAs in mouse fibroblasts. Mol Cell Biol. 5:1985;3280-3288.
64. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156-159.
65. Celano P, Vertino PM, Casero RA. Isolation of polyadenylated RNA from cultured cells and intact tissues. Biotechniques. 15:1993;27-28.